Late translational research: putting forward a new model for developing new anti‐cancer treatments that addresses the needs of patients and society-Reference-Cited by-同舟云学术

Late translational research: putting forward a new model for developing new anti‐cancer treatments that addresses the needs of patients and society

Published:2019-01-19 Issue:3 Volume:13 Page:558-566
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Lacombe Denis¹,Bogaerts Jan¹,Tombal Bertrand²,Maignen François³,Osipienko Leeza³,Sullivan Richard⁴,Golfinopoulos Vassilis¹

Affiliation:

1. EORTC Headquarters Brussels Belgium

2. Cliniques Universitaires Saint‐Luc Université Catholique de Louvain Brussels Belgium

3. NICE Scientific Advice National Institute for Health and Care Excellence London UK

4. Institute of Cancer Policy, Conflict and Health Research Group King's College London & Kings Health Partners Comprehensive Cancer Centre London, UK

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12431

Reference52 articles.

1. Public Health in the Precision-Medicine Era

2. Patient-centric trials for therapeutic development in precision oncology

3. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence

4. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?

5. A mission‐oriented approach to cancer in Europe: a joint mission/vision 2030

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH);PLOS ONE;2024-01-19

2. Translational Aspect of Cancer Nanomedicine: Present Status and Future Perspectives;Personalized and Precision Nanomedicine for Cancer Treatment;2024

3. Evaluating Collaboration in a Translational Research Ecosystem;Systems;2023-10-03

4. Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments;BMC Medical Research Methodology;2023-06-24

5. Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups;ESMO Open;2023-04